Changes of soluble CD40 ligand in the progression of acute myocardial infarction associate to endothelial nitric oxide synthase polymorphisms and vascular endothelial growth factor but not to platelet CD62P expression

Translational Research

Volumn 166, Issue 6, 2015, Pages 650-659

  Napoleaõ, Patrícia ^a   Monteiro, Maria Do Ceú ^b   Cabral, Luís B P ^b   Criado, Maria Begonã ^b   Ramos, Catarina ^c   Selas, Mafalda ^d   Viegas Crespo, Ana Maria ^e   Saldanha, Carlota ^a   Carmo, Miguel Mota ^d,f   Ferreira, Rui Cruz ^d   Pinheiro, Teresa ^c  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^c INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e UNIVERSITY OF LISBON   (Portugal)

^f UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; VASCULOTROPIN; CD40LIG FUSION PROTEIN; HYBRID PROTEIN; SELP PROTEIN, HUMAN; VASCULOTROPIN A;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENZYME POLYMORPHISM; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STABLE ANGINA PECTORIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; BLOOD; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; HEART INFARCTION; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; BLOOD PLATELETS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE TYPE III; P-SELECTIN; POLYMORPHISM, GENETIC; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84960481000     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.07.006     Document Type: Article

References (50)

1. F. Mach, U. Schönbeck, G.K. Sukhova, and et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis Proc Natl Acad Sci USA 94 1997 1931 1936
2. P. Aukrust, F. Müller, T. Ueland, and et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes Circulation 100 1999 614 620
3. R. Muhammad, D. Pathak, J.E. Freedman, and S. Chakrabarti CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease Trends Mol Med 14 2008 530 538
4. F. Santilli, S. Basili, P. Ferroni, and G. Davì CD40/CD40L system and vascular disease Intern Emerg Med 2 2007 256 268
5. E. Lutgens, D. Lievens, L. Beckers, M. Donners, and M. Daemen CD40 and its ligand in atherosclerosis Trends Cardiovasc Med 17 2007 118 123
6. B. Zhang, T. Wu, M. Chen, Y. Zhou, D. Yi, and R. Guo The CD40/CD40L system: A new therapeutic target for disease Immunol Lett 153 2013 58 61
7. N. Varo, J.A. de Lemos, P. Libby, and et al. Soluble CD40L: Risk prediction after acute coronary syndromes Circulation 108 2003 1049 1052
8. M. Brueckmann, T. Bertsch, S. Lang, and et al. Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes Clin Chem Lab Med 42 2004 1132 1139
9. S. Kinlay, G. Schwartz, A. Olsson, and et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study Circulation 110 2004 386 391
10. C. Urbich, E. Dernbach, A. Aicher, A.M. Zeiher, and S. Dimmeler CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species Circulation 106 2002 981 986
11. M.I. Furman, L.A. Krueger, M.D. Linden, M.R. Barnard, A.L. Frelinger III, and A.D. Michelson Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization J Am Coll Cardiol 43 2004 2319 2325
12. C. Chen, H. Chai, X. Wang, and et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells Blood 112 2008 3205 3216
13. M. Hristov, D. Gümbel, E. Lutgens, A. Zernecke, and C. Weber Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury Circulation 121 2010 315 324
14. D. Wolf, J.-D. Hohmann, A. Wiedemann, and et al. Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis-but does not affect immunity and thrombosis in mice Circ Res 109 2011 1269 1279
15. J.-Q. Luo, J.-G. Wen, H.-H. Zhou, X.-P. Chen, and W. Zhang Endothelial nitric oxide synthase gene G894T polymorphism and myocardial Infarction: A meta-analysis of 34 studies involving 21068 subjects PLoS One 9 2014 e87196
16. Ç. Çiftçi, S. Melil, Y. Çebi, and et al. Association of endothelial nitric oxide synthase promoter region (T-786C) gene polymorphism with acute coronary syndrome and coronary heart disease Lipids Health Dis 7 2008 5
17. E.J. Armstrong, David A. Morrow, and Marc S. Sabatine Inflammatory biomarkers in acute coronary syndromes. Part III: Biomarkers of oxidative stress and angiogenic growth factors Circulation 113 2006 e289 e292
18. G.S. Di Marco, Stefan Reuter, Uta Hillebrand, and et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD J Am Soc Nephrol 20 2009 2235 2245
19. D. Petrovic The role of vascular endothelial growth factor gene as the genetic marker of atherothrombotic disorders and in the gene therapy of coronary artery disease Cardiovasc Hematol Agents Med Chem 8 2010 47 54
20. C. Ramos, P. Napoleaõ, M. Selas, and et al. Prognostic value of VEGF in patients submitted to percutaneous coronary intervention Dis Markers 201 2014 135357
21. I. Chung, A. Choudhury, J. Patel, and G.Y.H. Lip Soluble CD40L, platelet surface CD40L and total platelet CD40L in congestive heart failure: Relationship to platelet volume, mass and granularity J Intern Med 263 2008 313 321
22. P. Napoleaõ, M.C. Santos, M. Selas, A.M. Viegas-Crespo, T. Pinheiro, and R. Cruz Ferreira Variations in inflammatory markers in acute myocardial infarction: A longitudinal study Rev Port Cardiol 26 2007 1357 1363
23. P. Napoleaõ, M. Selas, C. Freixo, and et al. The role of inflammatory biomarkers in the assessment of coronary artery disease B. Baskot, Coronary angiography- A dvances in noninvasive imaging approach for evaluation of coronary artery disease 2011 InTech, Rijeka
24. A. Dominguez-Rodriguez, P. Abreu-Gonzalez, M.J. Garcia-Gonzalez, and J.C. Kaski Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation Thromb Res 123 2009 617 621
25. E.R. Ahn, G. Lander, W. Jy, and et al. Differences of soluble CD40L in sera and plasma: Implications on CD40L assay as a marker of thrombotic risk Thromb Res 114 2004 143 148
26. N. Varo, R. Nuzzo, C. Natal, P. Libby, and U. Schönbeck Influence of pre-analytical and analytical factors on soluble CD40L measurements Clin Sci 111 2006 341 347
27. M.C. Monteiro, F. Sansonetty, M.J. Goncąlces, and J.E. O'Connor Flow cytometric kinetic assay of calcium mobilization in whole blood platelets using Fluo-3 and CD41 Cytometry 35 1999 302 310
28. L. Bernal-Mizrachi, W. Jy, C. Fierro, and et al. Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes Int J Cardiol 97 2004 439 446
29. R. Nieuwland, R.J. Berckmans, R.C. Rotteveel-Eijkman, and et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant Circulation 96 1997 3534 3541
30. F. Dignat-George, F. Sabatier, L. Camoin-Jau, and J. Sampol Measuring circulating cell-derived microparticles J Thromb Haemost 2 2004 1844 1845
31. A.S. Shet, N.S. Key, and R.P. Hebbel Measuring circulating cell-derived microparticles J Thromb Haemost 2 2004 1848 1850
32. M.G. Colombo, U. Paradossi, M.G. Andreassi, and et al. Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease Clin Chem 49 2003 389 395
33. V. Henn, S. Steinbach, K. Büchner, P. Presek, and R.A. Kroczek The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40 Blood 98 2001 1047 1054
34. A.-A. Weber, A. Hermann, B.H. Rauch, and K. Schrör Molecular identity of platelet CD40L ligand (CD40L) Thromb Haemost 86 2001 718
35. J. da Costa Escobar Piccoli, V. Manfredini, F.I. Hamester, and et al. Interaction between endothelial nitric oxide synthase gene polymorphisms (-786T>C, 894G>T and intron 4 a/b) and cardiovascular risk factors in acute coronary syndromes Arch Med Res 43 2012 205 211
36. M. Tesauro, W.C. Thompson, P. Rogliani, L. Qi, P.P. Chaudhary, and J. Moss Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. glutamate at position 298 Proc Natl Acad Sci USA 97 2000 2832 2835
37. A.D. Hingorani, C.F. Liang, J. Fatibene, and et al. A common variant of the endothelial nitric oxide synthase (Glu298/Asp) is a major risk factor for coronary artery disease in the UK Circulation 100 1999 1515 1520
38. Y. Hojo, U. Ikeda, Y. Zhu, and et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction J Am Coll Cardiol 35 2000 968 973
39. D. Petrovic, R. Verhovec, M. Globocnik Petrovic, J. Osredkar, and B. Peterlin Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes Cardiology 107 2007 291 295
40. H.S. Lim, M.H. Tayebjee, K.T. Tan, J.V. Patel, R.J. MacFadyen, and G.Y.H. Lip Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease? Thromb Res 122 2008 307 313
41. M. Melter, M.E.J. Reinders, M. Sho, and et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo Blood 96 2000 3801 3808
42. A.D. Blann, A. Choudhury, J. Freestone, J. Patel, and G.Y.H. Lip Soluble CD40 ligand and atrial fibrillation: Relationship to platelet activation, and endothelial damage/dysfunction Int J Cardiol 127 2008 135 137
43. A.G. Semb, S. van Wissen, T. Ueland, and et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: Downregulatory effect of statin therapy J Am Coll Cardiol 41 2003 275 279
44. H.F. Alber, M. Frick, A. Suessenbacher, and et al. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease-a randomized, placebo-controlled study Am Heart J 151 2006 139
45. E. Santini, S. Madec, V. Corretti, E. Ferrannini, and A. Solini Effect of statins on soluble CD40 ligand in hypercholesterolemic type 2 diabetic patients J Endocrinol Invest 31 2008 660 665
46. M.W. Park, S.H. Her, J.S. Cho, and et al. Triple antiplatelet therapy (aspirin, clopidogrel, cilostazol) loading followed by maintenance reduces greater serum level of sCD40L and TNF-a than dual antiplatelet therapy in patients with acute myocardial infarction undergoing PCI: Two-center, prospective, open label, randomized, pilot study Circulation 128 2013 A16074
47. C. Heeschen, S. Dimmeler, C.W. Hamm, and et al. Soluble CD40 ligand in acute coronary syndromes N Engl J Med 348 2003 1104 1111
48. J.C. Yan, J. Zhu, L. Gao, and et al. The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes Clin Chim Acta 343 2004 155 159
49. U. Schönbeck, N. Varo, P. Libby, J. Buring, and P.M. Ridker Soluble CD40L and cardiovascular risk in women Circulation 104 2001 2266 2268
50. A.A. Youssef, L.T. Chang, J.J. Sheu, and et al. Association between circulating level of CD40 ligand and angiographic morphologic features indicating high-burden thrombus formation in patients with acute myocardial infarction undergoing primary coronary intervention Circ J 71 2007 1857 1861